

NeuBase Therapeutics to Present at the LD Micro Conference

PITTSBURGH, PA , June 5, 2019 – NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer will present a corporate overview and business update at the LD Micro 9th Annual Invitational, being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

LD Micro 9th Annual Invitational

Date: Wednesday, June 5
Time: 10am Pacific Time, 1pm Eastern Time
Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
Webcast: <http://wsw.com/webcast/ldmicro16/nbt/>

About NeuBase Therapeutics

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

NeuBase Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 535-7746

NeuBase Media Contact:

Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366